Aberrant expression of FLI-1 in melanoma

被引:5
|
作者
Ramani, Nisha [1 ,2 ]
Aung, Phyu P. [1 ]
Hwu, Wen-Jen [3 ]
Nagarajan, Priyadharsini [1 ]
Tetzlaff, Michael T. [1 ,4 ]
Curry, Johnathan L. [1 ,5 ]
Ivan, Doina [1 ,5 ]
Prieto, Victor G. [1 ,5 ]
Torres-Cabala, Carlos A. [1 ,5 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA
[2] SUNY Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Dermatol, Houston, TX 77030 USA
关键词
FLI-1; melanoma; small round blue cell tumors; IMMUNOHISTOCHEMICAL DETECTION; CELL TUMORS; ROUND-CELL; ANTIBODY; TISSUE;
D O I
10.1111/cup.12979
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Friend leukemia integration site 1 (FLI-1) nuclear transcription factor has been proposed as a suitable tool in the differential diagnosis of small round cell sarcomas. It has also been described as a nuclear marker of endothelial differentiation. Expression of FLI-1 has been demonstrated in Ewing's sarcoma/primitive neuroectodermal tumor (ES/PNET) and vascular neoplasms. In the present study, we describe 2 cases of metastatic melanoma with small round blue cell morphology that showed strong nuclear expression of FLI-1. Because of the small round blue cell morphology and negative immunohistochemical staining for pan-melanocytic cocktail (HMB45, anti MART1 and anti-tyrosinase) and SOX10 in both cases, FLI-1 immunostaining was requested as part of the tumors workup. Ultimately, both cases were established as being metastatic melanoma. Dermatopathologists should be aware that melanoma can be strongly positive for FLI-1 and not misinterpret these cases for ES/PNET or vascular lesions, especially when melanomas show unusual morphology.
引用
收藏
页码:790 / 793
页数:4
相关论文
共 50 条
  • [41] FLI-1 inhibits differentiation and induces proliferation of primary erythroblasts
    Rui Pereira
    Christine Tran Quang
    Isabelle Lesault
    Helmut Dolznig
    Hartmut Beug
    Jacques Ghysdael
    Oncogene, 1999, 18 : 1597 - 1608
  • [42] FLI-1 is a suppressor of erythroid differentiation in human hematopoietic cells
    M Athanasiou
    G Mavrothalassitis
    L Sun-Hoffman
    DG Blair
    Leukemia, 2000, 14 : 439 - 445
  • [43] Drug-mediated inhibition of Fli-1 for the treatment of leukemia
    Y-J Li
    X Zhao
    L M Vecchiarelli-Federico
    Y Li
    A Datti
    Y Cheng
    Y Ben-David
    Blood Cancer Journal, 2012, 2 : e54 - e54
  • [44] The miRNA cluster miR-17-92 is a direct target of the transcription factors Fli-1 and Spi-1 acting downstream of Fli-1 in Friend Erythroleukemia
    Kayali, Samer
    Guyot, Boris
    Morle, Francois
    BULLETIN DU CANCER, 2011, 98 : S49 - S50
  • [45] Current insights into the role of Fli-1 in hematopoiesis and malignant transformation
    Ben-David, Yaacov
    Gajendran, Babu
    Sample, Klarke M.
    Zacksenhaus, Eldad
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2022, 79 (03)
  • [46] Drug-mediated inhibition of Fli-1 for the treatment of leukemia
    Li, Y-J
    Zhao, X.
    Vecchiarelli-Federico, L. M.
    Li, Y.
    Datti, A.
    Cheng, Y.
    Ben-David, Y.
    BLOOD CANCER JOURNAL, 2012, 2 : e54 - e54
  • [47] Current insights into the role of Fli-1 in hematopoiesis and malignant transformation
    Yaacov Ben-David
    Babu Gajendran
    Klarke M. Sample
    Eldad Zacksenhaus
    Cellular and Molecular Life Sciences, 2022, 79
  • [48] Regulation of megakaryocyte promoters by the oncogenic Ets factor Fli-1
    Bastian, LS
    Danner, S
    Roth, G
    BLOOD, 1998, 92 (10) : 350A - 350A
  • [49] FLI-1 inhibits differentiation and induces proliferation of primary erythroblasts
    Pereira, R
    Quang, CT
    Lesault, I
    Dolznig, H
    Beug, H
    Ghysdael, J
    ONCOGENE, 1999, 18 (08) : 1597 - 1608
  • [50] The ets transcription factor Fli-1 in development, cancer and disease
    Li, Y.
    Luo, H.
    Liu, T.
    Zacksenhaus, E.
    Ben-David, Y.
    ONCOGENE, 2015, 34 (16) : 2022 - 2031